Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Liver Biopsy
Interventions
biopsy
Diagnostic Test
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

Daytime vs. Delayed Eating Among Obese Individuals

NCT03354169
Conditions
Obesity
Interventions
Eating Condition, No Intervention; withdrawn before randomization
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Peripheral T-cell Lymphoma
Interventions
Romidepsin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
45
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 35 more
Conditions
Multiple Myeloma
Interventions
Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Crosse, Wisconsin
Active, not recruiting Early Phase 1 Interventional

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700
Conditions
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
Interventions
Niraparib, Resection/Treatment with Niraparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cannabis-Tobacco Co-Use Treatment Study

NCT06883162
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Interventions
Varenicline, Counseling, Psychosocial modules
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
Jonathan Trent, MD, PhD
Other
Eligibility
16 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 2 Interventional Accepts healthy volunteers

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
Conditions
Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions
L-Dopa, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Completed Phase 2 Interventional Results available

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

NCT00612430
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Etoposide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
PTSD, Alcohol Use Disorder
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 20 more
Conditions
Extreme Prematurity, Respiratory Distress Syndrome
Interventions
LISA
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
5 Minutes to 20 Minutes
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions
Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
Drug
Lead sponsor
Yih-Ing Hser
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

NCT00330434
Conditions
Alcohol Drinking, Depression, Smoking Cessation, Attention Deficit Disorder
Interventions
Trial Withdrawn 1, Trial Withdrawn 2
Other
Lead sponsor
Tufts University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation
Interventions
Abemaciclib, LY3214996
Drug
Lead sponsor
Anita Turk
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Recruiting Phase 3 Interventional Accepts healthy volunteers

Integrating Financial Coaching and Smoking Cessation Coaching

NCT05154669
Conditions
Smoking
Interventions
Financial counseling, Nicotine Replacement Therapy Agent - Patches, Nicotine Replacement Therapy Agent - Lozenges, Nicotine Replacement Therapy Agent - Gum
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Transplantation
Interventions
Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
Procedure · Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Understanding of Experiences With the SIMPLIFY Trial

NCT04320381
Conditions
Cystic Fibrosis, Drug Withdrawal
Interventions
Qualitative Interview
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Conditions
Prader-Willi Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more
Conditions
Melanoma
Interventions
ZK-EPO
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Hypertension
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more
Conditions
Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Everolimus, MLN0128, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Conditions
Colorectal Adenocarcinoma Metastatic in the Liver
Interventions
Pembrolizumab, Odetiglucan
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania